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112 Can vancomycin injection be nebulised successfully?
A. Bevan1, J. Chatoo1, M. Van Der Merwe2, G. Connett1. 1Southampton
University Hospitals NHS Trust, Southampton, United Kingdom; 2University of
Portsmouth, Portsmouth, United Kingdom
Aim: To evaluate whether off label nebulised vancomycin (Vancocin®) injection
can be delivered via Pari LC Plus™ and e-ﬂow rapid™ nebulisers.
Objectives: To measure particle size, proportion of drug remaining in the nebuliser,
degradation of product and percentage of drug delivered.
Method: Vancomycin 250mg (50mg/ml-500mg vial dissolved with 9.6ml water
for injection) were nebulised via both nebuliser systems. Particle size distribu-
tions were measured using a HELOS KF particle sizer (Sympatec, Germany)
at 4 representative ﬂow rates for children and adults. The proportion of drug
remaining and percentage delivered were calculated by measuring residual volume
and concentration. Sample degradation was evaluated by HPLC.
Results: Pari LC Plus™ − median particle sizes ranged from 1.75–2.18mm across
the 4 ﬂow rates; 61.6–73.9% of particles were between 1−5 mm in size. Of the
nebulised dose, 81.2% was delivered with 18.8% remaining in the nebuliser. The
residual concentration was 62.1mg/ml compared to 50mg/ml at initiation. There
was no degradation after nebulisation.
e-ﬂow rapid™ − median particle sizes ranged from 3.33−3.6 mm across the 4 ﬂow
rates; 61.7−70% of particles were between 1−5 mm. Of the nebulised dose, 74%
was delivered with 26% remaining in the nebuliser. The residual concentration was
48.8mg/ml compared with 50mg/ml initially. No degradation was seen.
Conclusion: It is possible to nebulise vancomycin injection via both the Pari LC
Plus™ and e-ﬂow rapid™ nebulisers. The characteristics of the inhalation vary
depending on the nebuliser used. It is not known if this is clinically signiﬁcant.
113 Safety, tolerability and pharmacokinetics of novel liposomal
ciproﬂoxacin formulations for inhalation in healthy volunteers (HV)
and non-cystic ﬁbrosis bronchiectasis (BE) patients
P. Bruinenberg1, D. Serisier2, D. Cipolla1, J. Blanchard1. 1Aradigm Corporation,
Hayward, United States; 2Mater Children’s Hospital, Brisbane, Australia
Ciproﬂoxacin (CP) for inhalation (CFI − [ARD-3100]) is an aqueous sustained
release liposomal formulation for respiratory infections in cystic ﬁbrosis (CF) and
non-CF BE patients. Dual release CP for inhalation (DRCFI − [ARD-3150]) is
a new inhaled formulation that matches the duration of release of CP from CFI,
supporting 1× day administration, while providing higher initial concentration of CP
in the lung to potentially provide enhanced concentration-dependent antimicrobial
effect. Inhaled CFI in HV was safe and well tolerated resulting in plasma PK with
an absorption-limited half life of 10.5 hr, compatible with 1× day administration.
A reduction in P. aeruginosa sputum density (p< 0.01) and an increase in FEV1
in CF patients were found. The current study evaluated the ability to modulate the
PK of CFI to provide a higher Cmax while maintaining the duration of release.
A single dose, cross-over trial comparing the safety, tolerability and plasma PK
of two inhaled formulations (CFI vs. DRCFI) was conducted in 8 adult HV and
DRCFI also in 6 BE subjects. Both formulations were safe and well tolerated in all
subjects. In HV, the mean CP Cmax for CFI (169 ng/mL) was 2.5 times greater than
for DRCFI (67 ng/mL) and the Tmax was faster for DRCFI (20 min vs. 1.8 hr). In
BE and HV, the mean half-life of CFI was 9.7 and 9.4 hr, respectively, vs. 10.8 hr
for CFI in HV. DRCFI matches the duration of release of CP from CFI, supporting
1× day dosing, while providing a spike of CP in the lung to potentially enhance
antimicrobial effects. High concentrations of CP was found in the sputum of BE
subjects. Ongoing clinical trials evaluating CFI (ARD-3100) and DRCFI (ARD-
3150) in CF are warranted.
114* Aspergillus fumigatus susceptibility to itraconazole in adult
patients with cystic ﬁbrosis
M. Amsellem1, P.-R. Burgel2, M.-T. Baixench1, D. Hubert2, R. Kanaan2,
J. Chapron2, D. Dusser2, A. Paugam1. 1Hoˆpital Cochin APHP, Universite´ Rene´
Descartes, Service de Mycologie-Parasitologie, Paris, France; 2Hoˆpital Cochin
APHP, Universite´ Rene´ Descartes, Service de Pneumologie, Paris, France
Background: Aspergillus fumigatus frequently colonizes the respiratory tract of
patients with CF and was isolated from specimens of 56% of patients at our CF
centre. Itraconazole (ITRA) is frequently prescribed in CF, especially in case of
allergic bronchopulmonary aspergillosis.
Objective: We hypothesised that A. fumigatus from CF patients who had been
treated with ITRA might have minimal inhibitory concentration (MIC) higher than
those from CF patients who had received no antifungal treatment.
Methods: From June to December 2010, patients with CF at our adult CF centre
had a systematic examination of sputum samples for the detection of fungi. In
all patients with A. fumigatus, susceptibility to ITRA was prospectively tested.
Sputum samples were cultured on Sabouraud agar and incubated for 10 days at
37ºC. A. fumigatus was identiﬁed on the basis of macroscopic and microscopic
morphology. Antifungal susceptibility was determined using the E-test method.
Results: We have tested 79 isolates of A. fumigatus from 79 patients (one sample by
patient). The proportion of A. fumigatus isolates with MIC for ITRA 2mg/ml was
36% (5/14) in the treated group versus 6% (4/65) in the untreated group (p< 0.05).
Interestingly the highest MICs (>32 mg/ml) were all observed in treated patients
(4/14) (29%) versus 0/65 untreated patients.
Conclusion: Our results demonstrate that the development of resistance of A. fu-
migatus to ITRA in adult patients with CF is clearly favored by prior antifungal
treatment. To avoid the emergence of resistant isolates of A. fumigatus to ITRA
in the CF population, it remains crucial to assess the real beneﬁt of prolonged
treatment with ITRA.
115 Comparison between voriconazole and posaconazole in
treatment of Aspergillus infections in cystic ﬁbrosis (CF) patients
P. Negle´n1, L. Mared1. 1Ska˚ne University Hospital, Dept of Respiratory Medicine
and Allergology, Lund, Sweden
Background: Voriconazole is recommended drug for treatment of Aspergillus
infections in patients with CF and primary ciliary dyskinesia (PCD). It was difﬁcult
to motivate patients to take voriconazole due to side effects.
Methods: Data were initially collected from patients’ records and the last two years
prospectively. Antifungal drugs were given to 34 patients (3 PCD) after having at
least two positive sputum cultures with Aspergillus sp.
Comparison between voriconazole (B) − posaconazole (C)
Treatments (patients) 32 (21) 16 (13)
Treatment length, mean (range) 144 (24–542) 106 (38–238)
Treatment length, median 98.5 111
Concentration, mean (range) mg/mL 0.63 (0.1–1.88) 1.18 (0.54–1.92)
Concentration, median, mg/mL 0.41 1.27
Total cost per treatment (euro) 17.197 13.880
Relapses (patients) 18 (12) 5 (4)
Time to relapse, mean, days (range) 381 (24–1506) 191 (45–431)
Time to relapse, median, days 189 64
Side effects (patients) 17 (14) 2 (2)
Main side effects for voriconazole is phototoxicity, sometimes leading to
pemphigus-like skin lesions with blisters, also after short periods of sun exposure.
Others are vomiting, vertigo, tachycardia, vision disturbances, photosensitivity,
hallucinations, fever, shivering and nightmares. Side effects for posaconazole were
gastric symptoms. Tiredness and nausea were side effects in both groups. Three
patients who relapsed on voriconazole also relapsed on posaconazole.
Conclusions: Treatment length is shorter, side effects and number of relapses are
fewer with posaconazole. Time to relapse is shorter with posaconazole. The total
cost per treatment is lower with posaconazole.
